Planned intervention: On Wednesday June 26th 05:30 UTC Zenodo will be unavailable for 10-20 minutes to perform a storage cluster upgrade.
Published March 31, 2022 | Version v4
Other Open

Operational Guidance (D4.4)

  • 1. Eli Lilly
  • 2. Steinbeißer Project Management
  • 3. CSL Behring
  • 4. Erasmus University of Rotterdam
  • 5. Novartis
  • 6. RTI
  • 7. AstraZeneca
  • 8. Merck KGaA
  • 9. Pharmagenesis
  • 10. KU Leuven
  • 11. KCE
  • 12. Amgen
  • 13. Uppsala University

Description

Along with the PREFER Recommendations, PREFER has developed operational guidance and training material to further assist in a patient preference study. The operational guidance consists of templates to utilize in the development and execution of a patient preference study.

Files

PREFER_Deliverable_4.4_Operational_Guidance 3.pdf

Files (322.7 kB)

Name Size Download all
md5:5f01e643faa55d766553216608c3f227
161.4 kB Preview Download
md5:ff44ed39edcc52ef867b7cf098b70b26
161.3 kB Preview Download

Additional details

Funding

PREFER – Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 115966
European Commission